×
Amgen Revenue 2010-2025 | AMGN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Amgen revenue for the twelve months ending March 31, 2025 was
$34.126B
, a
15.56% increase
year-over-year.
Amgen annual revenue for 2024 was
$33.424B
, a
18.57% increase
from 2023.
Amgen annual revenue for 2023 was
$28.19B
, a
7.09% increase
from 2022.
Amgen annual revenue for 2022 was
$26.323B
, a
1.32% increase
from 2021.
View More
Amgen Revenue 2010-2025 | AMGN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Amgen annual revenue for 2024 was
$33.424B
, a
18.57% increase
from 2023.
Amgen annual revenue for 2023 was
$28.19B
, a
7.09% increase
from 2022.
Amgen annual revenue for 2022 was
$26.323B
, a
1.32% increase
from 2021.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$209.6B
Gilead Sciences (GILD)
$130.2B
Vertex Pharmaceuticals (VRTX)
$125.6B
Bristol Myers Squibb (BMY)
$100.2B
CSL (CSLLY)
$74.3B
GSK (GSK)
$74.1B
Regeneron Pharmaceuticals (REGN)
$61.6B
Argenex SE (ARGX)
$36.2B
Alnylam Pharmaceuticals (ALNY)
$30.5B
BioNTech SE (BNTX)
$23.7B
BeiGene (ONC)
$22.8B
Biogen (BIIB)
$17.4B
Genmab (GMAB)
$13.3B
Genmab (GNMSF)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$11.3B
Illumina (ILMN)
$11.3B
Incyte (INCY)
$11.3B
Ascendis Pharma (ASND)
$10.1B
Exelixis (EXEL)
$10B
Swedish Orphan Biovitrum (BIOVF)
$9.6B
Moderna (MRNA)
$9.6B
QIAGEN (QGEN)
$9B
Exact Sciences (EXAS)
$7.7B
Bio-Techne Corp (TECH)
$7.6B
Repligen (RGEN)
$7.3B
Halozyme Therapeutics (HALO)
$7.3B
Roivant Sciences (ROIV)
$7.2B
Revolution Medicines (RVMD)
$6.8B
Bio-Rad Laboratories (BIO.B)
$6.3B